On October 17, Caitlin Sheetz, ADVI solution leader for Strategic Analytics, Value and Economics (SAVEs), presented an award-winning abstract on the Inflation Reduction Act (IRA) at the Academy of Managed Care Pharmacy (AMCP)’s Nexus conference.

This groundbreaking study, which was recognized by AMCP with a Platinum Award, evaluated the profound effects of the Inflation Reduction Act (IRA) and the $2,000 out-of-pocket spending cap on Medicare Part D beneficiaries.

This study marks ADVI’s first look into the patient population influenced by the new Part D benefit design and emphasizes the significant proportion of patients taking one of the first ten drugs subject to price negotiation who exceed the out-of-pocket threshold.

Hear more from Caitlin as she sheds light on key insights from the study and takeaways from AMCP Nexus. You can also view the poster for the presentation here: ADVI AMCP Nexus 2023 Poster.


Learn More

ADVI experts will continue to analyze the impact of the IRA as the new Part D benefit design and drug price negotiations evolve. Get in touch today to gain expert insights on the Inflation Reduction Act and the evolving healthcare landscape.


Caitlin Sheetz, MPH
Senior Vice President and Head of Strategic Analytics, Value and Economics

CEO insights

Real analysis from people who’ve been there

ADVI Health Accelerates Insights with Monthly Medicare Data

ADVI Health now has access to 100% of Medicare Parts A, B, and D research files with monthly availability – …

August 12, 2026

RAND/UCLA Modified Delphi Panels

ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …

Caitlin Sheetz, MPH
June 23, 2026

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

Health Policy & Access Strategy

How HEOR and Real-World Evidence Are Reshaping Decisions in 2026

By 2026, health economics and outcomes research (HEOR) and real-world evidence (RWE) will look less like a supporting function and …

February 10, 2026

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Inflation Reduction Act

What HEOR Information Does CMS Need for Drug Price Negotiations Under the IRA?

As the Inflation Reduction Act (IRA) reshapes drug pricing policy in the United States, the Centers for Medicare and Medicaid (CMS) …

December 1, 2025

Inflation Reduction Act

Real-World Effectiveness vs Clinical Trial Efficacy in Medicare

The Inflation Reduction Act (IRA) has ushered in a new era of drug pricing negotiations in the US. For the …

October 1, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.